What are the hospice eligibility criteria for patients with chronic bronchiectasis?

Hospice Eligibility Criteria for Chronic Bronchiectasis

Patients with chronic bronchiectasis qualify for hospice when they meet Medicare criteria for advanced lung disease: severe disabling dyspnea at rest with bed-to-chair existence, progressive disease with increasing hospitalizations/ED visits, and hypoxemia (PO2 ≤55 mmHg or O2 sat ≤88% on supplemental oxygen) or hypercapnia (PCO2 >50 mmHg). 1

Core Required Criteria

The Medicare hospice eligibility framework applies to bronchiectasis as part of end-stage pulmonary disease. Two primary criteria must be present 1:

1. Severe Chronic Lung Disease (Both a AND b required):

• (a) Disabling dyspnea at rest that is poorly or unresponsive to bronchodilators, resulting in:

  • Decreased functional capacity (bed-to-chair existence)
  • Significant fatigue
  • Persistent cough
  • Note: FEV1 <30% predicted after bronchodilator provides objective evidence but is not mandatory

• (b) Progression of end-stage disease evidenced by:

  • Increasing ED visits or hospitalizations for pulmonary infections and/or respiratory failure
  • Increasing physician home visits before certification
  • Note: Serial FEV1 decline >40 mL/year provides objective evidence but is not mandatory

2. Gas Exchange Abnormality (Any ONE of):

• PO2 ≤55 mmHg on room air
• Oxygen saturation ≤88% despite supplemental oxygen
• PCO2 >50 mmHg (hypercapnia)

These values can be obtained from hospital records within the past 3 months 1

Supporting Documentation (Strengthens Eligibility)

While criteria 1 and 2 are essential, the following provide additional supporting evidence 1:

1. Right heart failure secondary to pulmonary disease (cor pulmonale)

   • Must be due to lung disease, not left heart disease or valvular pathology

2. Unintentional progressive weight loss >10% of body weight over preceding 6 months

3. Resting tachycardia >100 beats/minute

Critical Clinical Context

The Prognostic Challenge

A major caveat: these criteria have poor predictive accuracy for 6-month survival. Research demonstrates that even with narrow inclusion criteria, 53% of patients survived beyond 6 months, and with broader criteria, 70% survived longer than expected 2. This reflects the inherently unpredictable trajectory of advanced lung disease compared to malignancy 3.

Practical Application

Despite imperfect prognostic accuracy, do not delay hospice referral waiting for patients to meet every criterion perfectly 4. The evidence shows:

• 60% of terminally ill patients were hospice-eligible during their penultimate admission, yet only 14% had documented hospice discussions 4
• Patients with advanced bronchiectasis often have stepwise decline with multiple hospitalizations before death 4

Documentation Strategy

For bronchiectasis patients who appear to be declining but don't meet strict criteria, document "evidence of rapid decline" including 5:

• Frequency of exacerbations requiring antibiotics
• Recurrent respiratory infections (particularly with Pseudomonas aeruginosa, which portends worse outcomes) 6
• Progressive functional decline
• Increasing oxygen requirements
• Declining nutritional status

Common Pitfalls to Avoid

1. Waiting for terminal admission: Initiate hospice discussions during earlier hospitalizations when patients show progressive decline 4

2. Overreliance on spirometry: FEV1 values support but are not required; clinical assessment of dyspnea and functional status is paramount 1

3. Ignoring comorbidities: Bronchiectasis patients often have COPD (20%), asthma (29%), or GERD (47%) that compound their decline 6

4. Missing the recertification option: If patients stabilize beyond 6 months, they can be recertified if they continue to meet criteria 5